TransCode Therapeutics announced the acceptance of a patent application in Australia and the issuance of a patent in Japan for its RNA-based cancer therapy technologies. These patents cover innovative nanoparticle delivery systems and RNA compositions designed to target and modulate immune responses in various cancers. This strengthens TransCode's intellectual property portfolio and supports its development of advanced RNA therapeutics aimed at treating difficult cancers. The company’s progress highlights its commitment to combining gene silencing and immune activation for improved cancer treatment outcomes.
TransCode Therapeutics' patent advancements in Australia and Japan provide context for readers interested in innovative biotech developments. For readers following the health sector, here is Pluang's market snapshot as of Sep 22, 2026 18:11 WIB: Out of 95 priced US health stocks, 50 rose and 38 fell. FLNA traded at USD 0.73 with a 1-day change of -1.04% and a typical hold time of 39 days, contrasting with DNA at USD 7.90, which saw a -1.00% change and a much shorter hold time of 11 days. REGN stood out at USD 790.72 with a -0.93% change and a notably longer hold time of 106 days, while order activity varied widely among these stocks.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
